Tandem Diabetes Care, a prominent leader in insulin delivery technology and diabetes management solutions, announced a significant leadership transition on Thursday, naming Jeannette Bankes as its next President and Chief Executive Officer. Bankes is slated to assume her new responsibilities on November 16, 2026, taking over from John Sheridan, who has served as the company’s chief executive since 2019. Sheridan, a pivotal figure in Tandem’s growth over the last decade, will remain with the organization through the end of the year to ensure a seamless handover before transitioning into a consultative role.
The announcement comes at a critical juncture for the San Diego-based medical technology firm, which is currently navigating a period of rapid product evolution and expansion into new market segments. Sheridan, 70, noted during a Thursday earnings call that the timing of his retirement was the result of long-term succession planning conducted in coordination with the company’s board of directors. He expressed unwavering confidence in Bankes, citing her extensive background in the global healthcare sector and her proven track record of driving operational excellence.
The Incoming Executive: A Profile of Jeannette Bankes
Jeannette Bankes joins Tandem Diabetes Care following a highly successful tenure at GE HealthCare, where she served as the CEO of the Patient Care Solutions (PCS) business. In that role, she managed a diverse and complex $3.1 billion portfolio that included patient monitoring systems, diagnostic cardiology, and anesthesia delivery products. Her leadership at GE HealthCare was characterized by a focus on improving profitability and accelerating growth across international markets, experiences that are expected to be directly applicable to Tandem’s global ambitions.
Prior to her time at GE HealthCare, Bankes held several senior leadership positions at Alcon, where she served as the president of global franchises. Her career also includes significant experience at other major medical device firms, including Boston Scientific, where she spent over a decade in various management roles. With more than 30 years of experience in the medtech industry, Bankes is viewed by analysts as a strategic hire capable of scaling Tandem’s operations as it transitions from a niche pump manufacturer to a comprehensive diabetes technology provider.
According to Tandem’s latest quarterly SEC filing, Bankes will receive an annual base salary of $900,000. Her compensation package is designed to align with industry standards for mid-cap medical technology companies, likely including performance-based equity incentives tied to the company’s long-term growth and stock performance.
The Legacy of John Sheridan: 2013–2026
John Sheridan’s departure marks the end of an era for Tandem Diabetes Care. Sheridan joined the company in 2013 as Chief Operating Officer, a time when the firm was still establishing its presence in a market dominated by larger incumbents like Medtronic. Under his operational leadership and subsequent tenure as CEO starting in 2019, Tandem transformed from a struggling startup into a major market contender.
The most notable achievement of the Sheridan era was the successful launch and iteration of the t:slim X2 insulin pump. By integrating Control-IQ technology—an advanced automated insulin delivery (AID) algorithm—Tandem provided patients with a system capable of automatically adjusting insulin levels to prevent both highs and lows. This innovation was a primary driver of the company’s market share gains, particularly among Type 1 diabetes patients.
More recently, Sheridan oversaw the development and launch of the Tandem Mobi, marketed as the world’s smallest durable insulin delivery system. The Mobi represented a significant departure from traditional pump design, offering a wearable, miniaturized form factor controlled entirely via a smartphone application. Sheridan’s strategic focus on user experience and digital integration has set the stage for the company’s current product pipeline.
Strategic Objectives and the Mobi Tubeless Transition
As Bankes prepares to take the helm, Tandem is focused on several high-stakes initiatives that will define its success in the coming years. Chief among these is the launch of the Mobi Tubeless option. Currently, the insulin pump market is bifurcated between traditional "tubed" pumps and "patch" pumps, the latter of which is currently dominated by Insulet’s Omnipod system.
Tandem’s Mobi was designed to be versatile; while it currently utilizes a short infusion set, the company is seeking FDA clearance for a "tubeless" version that would allow the device to be worn directly on the body without any external tubing. Sheridan confirmed on Thursday that the Mobi Tubeless is in the late stages of review with the Food and Drug Administration. The successful launch of this product is seen as essential for Tandem to compete effectively for patients who prefer the discretion and convenience of a patch-style pump.
Furthermore, Tandem is aggressively pursuing a shift in its distribution model. Historically, insulin pumps have been categorized as Durable Medical Equipment (DME), which often involves complex billing and high upfront costs for patients. Under Sheridan’s guidance, Tandem began a transition toward the pharmacy channel, aiming to make its products accessible through standard prescription benefits. This shift is intended to lower the barrier to entry for patients and align the company’s business model with the way modern continuous glucose monitors (CGMs) are sold.
Future Frontiers: Fully Closed-Loop Systems and Type 2 Diabetes
Looking beyond the immediate hardware launches, Tandem is investing heavily in the next generation of automated insulin delivery. The company is currently collaborating with researchers at the University of Virginia (UVA) to develop a "fully closed-loop" system. Unlike current "hybrid" closed-loop systems, which require users to manually input carbohydrate counts and "announce" meals, a fully closed-loop system would use advanced algorithms to manage glucose levels autonomously without user intervention.
Tandem plans to initiate a pivotal clinical study for this technology before the end of 2026. If successful, this would represent a landmark achievement in diabetes care, offering a "set-and-forget" solution that could significantly reduce the cognitive burden of managing Type 1 and insulin-intensive Type 2 diabetes.
The expansion into the Type 2 diabetes market is another pillar of the company’s growth strategy. While Tandem has traditionally focused on Type 1 patients, the rising prevalence of insulin-dependent Type 2 diabetes presents a massive, under-penetrated market. The company’s focus on smaller, more discrete devices like the Mobi is specifically intended to appeal to this demographic, which often seeks simpler, less invasive technology.
Competitive Landscape and Market Analysis
The leadership transition at Tandem occurs within a highly competitive global landscape. The company’s primary rivals, Medtronic and Insulet, have also been active in refreshing their product lines. Insulet’s Omnipod 5 has seen rapid adoption due to its tubeless design and integrated AID features, while Medtronic has sought to regain lost ground with its MiniMed 780G system.
Market analysts suggest that Bankes’ background in large-scale healthcare operations will be vital as Tandem seeks to maintain its growth trajectory in the face of these competitors. The company must balance its high R&D spending with a need for sustained profitability. In its most recent earnings report, Tandem showed resilient sales growth, but investors remain focused on the company’s ability to successfully navigate the regulatory hurdles of the Mobi Tubeless launch and the long-term clinical trials for its fully automated system.
Industry observers also point to the potential impact of GLP-1 medications on the diabetes technology market. While there were initial concerns that these drugs might reduce the need for insulin pumps, current data suggests that the two therapies are often complementary, particularly for patients with advanced Type 2 diabetes. Bankes will likely need to navigate this evolving therapeutic landscape to ensure Tandem’s technology remains a cornerstone of diabetes management.
Chronology of Leadership and Innovation at Tandem
To understand the significance of this transition, it is helpful to look at the timeline of Tandem’s evolution:
- 2013: John Sheridan joins Tandem Diabetes Care as Chief Operating Officer.
- 2016: The company receives FDA clearance for the t:slim X2, the first pump capable of remote software updates.
- 2019: John Sheridan is appointed President and CEO; Tandem launches Control-IQ technology.
- 2020–2022: Tandem expands its global footprint, entering European and Asia-Pacific markets.
- 2023: The company receives FDA clearance for the Tandem Mobi, the smallest durable pump on the market.
- Early 2026: Tandem submits the Mobi Tubeless for FDA review and continues expansion into the pharmacy channel.
- November 6, 2026: Tandem announces the appointment of Jeannette Bankes as CEO and the retirement of John Sheridan.
- November 16, 2026: Jeannette Bankes officially assumes the role of CEO.
- December 31, 2026: John Sheridan officially retires from his employee role, moving to a consultancy.
Conclusion: A New Chapter for Tandem
The appointment of Jeannette Bankes signals Tandem Diabetes Care’s readiness to enter its next phase of maturity. By selecting a leader with deep experience in multi-billion-dollar healthcare portfolios, the board has indicated that Tandem is no longer just a "pump company," but a global medical technology powerhouse.
John Sheridan leaves behind a legacy of patient-centered innovation that fundamentally changed how insulin is delivered. His tenure saw the company move from the fringes of the industry to a leadership position, characterized by the successful integration of software, hardware, and clinical algorithms.
As Bankes takes the reins, her primary challenges will be the successful commercialization of the Mobi Tubeless system, the continued penetration of the Type 2 diabetes market, and the realization of the "holy grail" of diabetes care: the fully closed-loop system. With a robust pipeline and a clear strategic vision, Tandem Diabetes Care appears well-positioned to continue its mission of improving the lives of people with diabetes under its new leadership.
